Excellos Launches Cell Therapy Manufacturing Newsletter: Innovation Updates in CAR-T and GMP Production
Find how you can see state-of-the-art manufacturing, why decentralized manufacturing makes sense, and why mito functions are key to selecting CAR-T donors. Excellos Newsletter Launches Focusing on Innovations in Cell Therapy Manufacturing Find how you can see state-of-the-art manufacturing, why decentralized manufacturing makes sense, and why mito functions are key to selecting CAR-T donors. Welcome […]
Spotlight on Excell-ence: Project Management Team
Excellos project management team At Excellos, our success is built on the expertise and dedication of our incredible teams. In this ongoing series, we’re highlighting the people behind the innovation—showcasing the teams that make our work possible. First up, our Project Management Team: the experts ensuring seamless execution and unparalleled customer support. Meet Erin Darnley, […]
Excellos & SDBB: A Legacy of Innovation and Impact
Excellos: From Blood Bank Division to Leading Cell Therapy CDMO | A Legacy of Innovation At Excellos, we are driven by a mission that seamlessly blends cutting-edge science with a legacy of service. Our journey began as a division of the San Diego Blood Bank (SDBB), a nonprofit with over 70 years of experience in […]
Excellos Ensures Reliability and Patient Safety with XiltriX
This case study is available as a downloadable PDF for offline reading.
Choosing the right PBMCs for your research and product development needs
What you need to know about choosing peripheral blood mononuclear cells for your research and development projects What are PBMCs? Human peripheral blood mononuclear cells (PBMCs) are key components of the body’s immune system. PBMCs are typically isolated from whole blood by apheresis and used for a variety of downstream applications, such as feeder […]
Allogeneic Cell Therapy Advances at AACR 2024
American Association for Cancer Research (AACR) held their 2024 annual meeting in San Diego CA. This conference served as a platform for groundbreaking advancements in allogeneic cell therapy highlighted across a range of diseases. Safeguarding allogeneic cell therapy products Among the noteworthy developments were discoveries from Century Therapeutics whose presentation of preclinical data revealed […]
3 Key Bottlenecks in Cell Therapy Supply Chains
Cell Therapy Supply Chain With 1920 ongoing clinical trials as of Q4 2023, the pipeline for new therapies is rich in diversity of diseases under investigation and is continuing to grow. A major follow-on question is whether the gene and cell therapy supply chain is ready to handle what may be a tidal wave of […]
Autoimmune Therapy Excitement Builds at Advanced Therapies Week 2024
Robust pipeline demonstrated at Advanced Therapies Week 2024 As we reflect on the monumental strides made in 2023 within the field of cell and gene therapy, Advanced Therapies Week 2024 served as an inspiring launchpad for the year ahead. Groundbreaking approvals like gene therapies for sickle cell disease brought hope for rare illnesses, while advances […]
Excellos is excited to partner with TC BioPharm to enable novel cell therapies
TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements EDINBURGH, Scotland, Oct. 25, 2023 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced it has selected Excellos, a San Diego based […]
Single-Cell Analysis of T Cells – Improved Prediction of Disease Risk
The La Jolla researchers are studying how small changes in gene expression can influence the function of immune cells during infection. Single-cell analysis was performed on activated CD4+ T cells from 89 healthy donors. It turns out that the old adage of “one gene, one protein” is not precisely true. In reality, as research on […]